GPs and Specialists in UK are Challenging the Restrictions That Deny Patients Access to Treatment

Dr. David Porteous, a General Practitioner in Bristol, England recently reported to the Bristol Cable, a community-run newspaper, that he does not agree with the extensive list of treatments being…

Continue Reading GPs and Specialists in UK are Challenging the Restrictions That Deny Patients Access to Treatment

In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

Ash Clinical News recently interviewed Dr. Bruce Leff of Johns Hopkins in connection with “hospital-at-home”, one of the major changes occurring in hospital care. Dr. Leff and his team at…

Continue Reading In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

International Meeting for Patients and Researchers Held for Stevens-Johnson Syndrome

Stevens-Johnson Syndrome Stevens-Johnson Syndrome (SJS), otherwise known as toxic epidermal necrolysis, is a rare disease caused by allergic reactions to common drugs or a reaction to an infection. Some of…

Continue Reading International Meeting for Patients and Researchers Held for Stevens-Johnson Syndrome

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

Positive Updates for a New Potential Gene Therapy for Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome Wiskott-Aldrich Syndrome (WAS) is a rare immune disorder which causes platelets in the blood to function abnormally. It also causes autoimmunity. Patients suffer from severe bleeding which can…

Continue Reading Positive Updates for a New Potential Gene Therapy for Wiskott-Aldrich Syndrome
Electrical Spine Implant Could Restore Mobility in Some Parkinson’s Patients
Source: Pixabay

Electrical Spine Implant Could Restore Mobility in Some Parkinson’s Patients

According to a publication from the BBC, a novel new technology could help some with Parkinson's disease regain limited walking ability. However, unlike medical technology we often showcase on Patient…

Continue Reading Electrical Spine Implant Could Restore Mobility in Some Parkinson’s Patients
Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
https://pixabay.com/en/technology-robot-human-hand-2025795/

Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run

According to an article from CW associate WBCB, Dutch startup Nori Health has started open enrollment in the six-week test of its eponymous experimental chatbot, Nori. Nori aims to help…

Continue Reading Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run

Study Aims to Improve Patient Centricity in Huntington’s Disease Clinical Trials

As the medical field continues to advance, treatments are becoming less and less "traditional" because researchers are uncovering unique ways to combat illnesses. Therapies range from pills, to surgery, to…

Continue Reading Study Aims to Improve Patient Centricity in Huntington’s Disease Clinical Trials
More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III
kkolosov / Pixabay

More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

According to a press release from the American Academy of Neurology published by EurekAlert, new research published in Neurology further suggests that established spinal muscular atrophy (SMA) drug nusinersen could…

Continue Reading More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

Research Shows Promise Restoring Myelin in Mice with Simulated Multiple Sclerosis

According to an article from Medical Xpress, an experimental chemical compound being developed by Oregon Health & Science University (OHSU) has proven effective in reversing simulated symptoms of multiple sclerosis…

Continue Reading Research Shows Promise Restoring Myelin in Mice with Simulated Multiple Sclerosis
First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug
Source: Pixabay.com

First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug

According to a press release from biotechnology company Forbius (Formation Biologics Inc.), the first patient in the Company's phase 1b trial of experimental myelofibrosis (MF) drug AVID200 has successfully received…

Continue Reading First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug

Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are both rare and chronic liver diseases. They cause the bile ducts in the liver to become inflamed, resulting in severe liver damage.…

Continue Reading Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Continue Reading Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome
Close Menu